CD58 Expression Decreases as Nonmalignant B Cells Mature in Bone Marrow and Is Frequently Overexpressed in Adult and Pediatric Precursor B-cell Acute Lymphoblastic Leukemia

Lee, Ronald V.; Braylan, Raul C.; Rimsza, Lisa M.

doi:10.1309/x5vv-6fkj-q6mu-blpx

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an early study, this approach led to the identification of CD58 as a useful marker (57), a finding which was confirmed by several other studies (58)(59)(60)(61). More recently, a study compared genome-wide gene expression of leukemic cells from 270 patients with B-lineage ALL to that of purified normal CD19…”

Section: Immunological Markers Of Mrd In All: Evolutionmentioning

confidence: 65%

Detection of minimal residual disease in pediatric acute lymphoblastic leukemia

Gaipa

Basso

Biondi

et al. 2013

Cytometry Part B Clinical

View full text Add to dashboard Cite

Minimal residual disease (MRD) is a powerful predictor of the overall response to treatment in childhood acute lymphoblastic leukemia (ALL). INTRODUCTIONMost children with acute lymphoblastic leukemia (ALL) achieve complete remission with current treatment regimens but leukemia relapse, the main cause of treatment failure, still occurs in a significant proportion of patients (1). Periodic assessment of treatment response provides an indication of the sensitivity of leukemic cells to chemotherapy and of the overall treatment effectiveness. Historically, treatment response has been monitored by morphological examination of bone marrow aspirates, a task which is a fundamental component of the clinical care of patients with ALL (2). Because this approach has a limited sensitivity and specificity, it can result in failure to detect residual leukemic cells, potentially leading to under-treatment and an increase risk of relapse. Conversely, misclassification of normal cells as ALL blasts may result in over-treatment and an increase in the risk of treatment-related morbidity.Over the last 2-3 decades, much effort has been made to develop accurate and sensitive methods that could determine response to treatment more precisely than morphology, and to detect residual leukemia persisting in patients considered to be in morphologic remission, i.e. minimal residual disease (MRD) (3,4). Many studies have demonstrated that MRD is a powerful predictor of clinical outcome in childhood ALL (5-12), supporting the use of a more stringent definition of hematological remission based on MRD assays rather than morphology (13). METHODOLOGIES FOR MRD DETECTIONTo be informative, MRD assays for ALL should allow to the detection of one leukemic cell among 10,000 normal cells or more. They should also reliably discriminate leukemic and normal cells, and allow a timely output of (14)(15)(16)(17)(18). Currently, the most reliable methods to study MRD in ALL are flow cytometric (FCM) analysis of leukemia-associated immunophenotypes (i.e., aberrant phenotypes expressed in leukemic cells but not in normal bone marrow or peripheral blood cells), and polymerase chain reaction (PCR) amplification of antigen receptor gene rearrangements (2,14-23); gene fusion transcripts can also be used as PCR targets in some cases (24). The main features of these techniques are outlined in Table 1. A BRIEF HISTORY OF THE DEVELOPMENT OF MULTICOLORFLOW CYTOMETRY IMMUNOPHENOTYPING Antigen expression is assessed by quantification of the signal emitted by fluorochrome-conjugated-specific monoclonal antibodies (MoAb). Fluorescein excited by an argon laser was initially used in the Herzenberg laboratory, followed by two-color fluorescence detection (25).Then, additional antibody-conjugated fluorochromes were developed to increase the number of "colors" (26). From the 1980s, the capacity of several molecules to absorb and transfer energy to other fluorescent molecules was exploited to produce tandem dyes such as PETexas Red, PE-Cy5, PE Cy7, and Alexa (27,28), thus many la...

show abstract

Section: Immunological Markers Of Mrd In All: Evolutionmentioning

confidence: 65%

Detection of minimal residual disease in pediatric acute lymphoblastic leukemia

Gaipa

Basso

Biondi

et al. 2013

Cytometry Part B Clinical

View full text Add to dashboard Cite

show abstract

“…In addition, CD38 + CD58- is an independent poor prognostic factor in pediatric patients with Ph − B-cell ALL, who have shorter survival and higher risk of relapse ( 192 ). As nonmalignant B cells differentiate from early to mature stages in the bone marrow, the expression of CD58 gradually reduces, while it is usually upregulated in pediatric and adult B-cell ALL ( 193 ). The expression of CD58 is remarkably higher in ALL blasts than that in normal B cells, whereas there is no significant difference between regenerated and normal B cells ( 194 ).…”

Section: Hematological Malignanciesmentioning

confidence: 99%

CD58 Immunobiology at a Glance

et al. 2021

View full text Add to dashboard Cite

The glycoprotein CD58, also known as lymphocyte-function antigen 3 (LFA-3), is a costimulatory receptor distributed on a broad range of human tissue cells. Its natural ligand CD2 is primarily expressed on the surface of T/NK cells. The CD2-CD58 interaction is an important component of the immunological synapse (IS) that induces activation and proliferation of T/NK cells and triggers a series of intracellular signaling in T/NK cells and target cells, respectively, in addition to promoting cell adhesion and recognition. Furthermore, a soluble form of CD58 (sCD58) is also present in cellular supernatant in vitro and in local tissues in vivo. The sCD58 is involved in T/NK cell-mediated immune responses as an immunosuppressive factor by affecting CD2-CD58 interaction. Altered accumulation of sCD58 may lead to immunosuppression of T/NK cells in the tumor microenvironment, allowing sCD58 as a novel immunotherapeutic target. Recently, the crucial roles of costimulatory molecule CD58 in immunomodulation seem to be reattracting the interests of investigators. In particular, the CD2-CD58 interaction is involved in the regulation of antiviral responses, inflammatory responses in autoimmune diseases, immune rejection of transplantation, and immune evasion of tumor cells. In this review, we provide a comprehensive summary of CD58 immunobiology.

show abstract

“…13 The geometric mean fluorescence intensities within the lymphocyte gate of the isotype control tube (MFIIsotype) were used to standardize mean fluorescence intensities of lymphocyte subpopulations (mean fluorescence intensity ratio [MFIR]=geometric mean of lymphocyte subpopulation/MFIIsotype), as described elsewhere. 30,31 The upper limits of lymphocyte fluorescence intensity distributions for underexpressed antigens were standardized accordingly (e.g. 95% fluorescence intensity ratio In accordance with the literature on MRD in acute leukemias [32][33][34][35] and our experience in chronic lymphocytic leukemia 21 we defined that at least 20 positive events forming a population were required as evidence for MRD.…”

Section: Flow Cytometrymentioning

confidence: 99%